Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of High Dose Dabigatran Etexilate in Healthy Subjects
NCT02171455Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2006
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of dabigatran in thromboembolism (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Frequency of subjects with adverse events up to 18 days. Started Jan 2006; status: completed.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02171455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171455.